Transthyretin amyloid cardiomyopathy (ATTR-CM) is associated with progressive heart failure and at present, few disease-modifying treatments exist. NNC6019-0001 is a humanized monoclonal antibody designed to deplete amyloid fibrils that result in heart failure. In this touchCARDIO interview, we speak with Professor Marianna Fontana (National Amyloidosis Centre, University College London, Royal Free Campus, London, UK) to discuss the phase II study investigating NNC6019-0001 in patients with AATR-CM.
The abstract entitled ‘NNC60190001, a humanized monoclonal antibody, in patients with transthyretin amyloid cardiomyopathy (ATTRCM): rationale and study design of a phase 2, randomized, placebo controlled trial’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- What is NNC6019-0001 and what is its mechanism of action? (0:22)
- What were the methodology and eligibility criteria of your study investigating NNC6019-0001? (1:35)
- What are the primary and secondary endpoints of the study? (2:33)
- When are results expected? (3:05)
Disclosures: Marianna Fontana is on the advisory board and a consultant for Alexion, Alnylam, Caelum, Intellia, Ionis, Jannsen, Novo Nordisk and Pfizer.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Heart Failure here
